Tenderwize
Back to tender search

Open-House Biologics Discount Agreements 2026-13 - Romiplostim

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 29, 2028 · 681 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-13 - Romiplostim

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

15 / 100

Risk factors

The agreement does not guarantee any sales volume; actual demand depends on prescription behavior and competition from...

This is not a public procurement; legal remedies lie with social courts, not procurement chambers. Different rules appl...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Supply of pharmaceutical products containing Romiplostim.
  • Conclusion of discount agreements with health insurance funds (Techniker Krankenkasse, HEK, hkk).
Show full summary

This is an Open-House procedure to conclude discount agreements (Rabattverträge) for the active substance Romiplostim under §130a SGB V. All eligible pharmaceutical entrepreneurs can join at any time during the contract period (up to 24 months). No exclusivity is granted, and no guaranteed volume. The procedure is not a public procurement according to EU directives; legal disputes go to social courts.

Risks

The agreement does not guarantee any sales volume; actual demand depends on prescription behavior and competition from...

This is not a public procurement; legal remedies lie with social courts, not procurement chambers. Different rules appl...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of §4(18) AMG with valid marketing authorization for Romiplostim.
  • Must have seat in Germany, EU, or EEA.

Administrative

  • Must submit a self-declaration on admission and reliability (Anlage 4).

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Agreements 2026-13 - Romiplostim

Conclusion of drug discount agreements for Romiplostim with eligible pharmaceutical entrepreneurs under an Open-House procedure.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Jun 2026 - Jun 2028

Category

Pharmaceutical products

Deadline

Deadline Jun 29, 2028

Procurement Details

Publication date
07 May 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
318965-2026

Documents (1)

Similar tenders